Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating

Investing.com - Cantor Fitzgerald initiated coverage on Tvardi Therapeutics Inc (NASDAQ:TVRD) with an Overweight rating and a price target of $52.00 on Friday. The $212 million market cap company currently trades at $22.67, with analysts setting targets between $41 and $78. According to InvestingPro data, TVRD has shown strong momentum with a 24% return over the past six months.

The research firm’s coverage focuses on Tvardi’s lead program, oral STAT3 inhibitor TTI-101, which it identifies as the primary driver of its investment thesis.

TTI-101 is currently in an ongoing proof-of-concept study for idiopathic pulmonary fibrosis (IPF), with data expected in the fourth quarter of 2025.

Cantor Fitzgerald expects the upcoming data from the 75-patient Phase 2 IPF study to validate STAT3 inhibition as a treatment approach for IPF.

The firm believes positive results could potentially expand TTI-101’s applications to other fibrotic diseases beyond IPF.

In other recent news, Tvardi Therapeutics Inc has been the focus of several analyst updates following its recent reverse merger with Cara Therapeutics. The company’s financial position is bolstered by approximately $46.1 million in proforma cash, which is expected to sustain operations into the second half of 2026. Piper Sandler initiated coverage with an overweight rating, highlighting the potential of Tvardi’s lead asset, TTI-101, which is currently in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF). The firm believes the drug’s unique mechanism could offer broad improvements in treatment outcomes.

BTIG analyst Julian Harrison reiterated a Buy rating with a $55 price target, emphasizing the potential of TTI-101 to reverse disease progression in IPF, a significant advancement over existing treatments. Oppenheimer also initiated coverage with an Outperform rating and a $65 target, noting the drug’s potential in both IPF and hepatocellular carcinoma (HCC). The firm forecasts risk-adjusted peak sales of $1.2 billion by 2040, based on promising interim trial data.

Lucid (NASDAQ:LCID) Capital Markets set a $42 price target, citing TTI-101’s potential to capture a significant share of the IPF market, currently dominated by Ofev and Esbriet. The firm also mentioned upcoming data for TTI-101 in HCC, with peak sales estimated at $298 million by 2039. Tvardi is advancing TTI-109, a prodrug of TTI-101, towards an IND application, contributing to the overall valuation. These developments reflect a positive outlook on Tvardi’s prospects in the biotech sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.